Skip to main content
. Author manuscript; available in PMC: 2011 Apr 13.
Published in final edited form as: Eur J Immunol. 2009 Nov;39(11):3084–3090. doi: 10.1002/eji.200939407

Figure 1.

Figure 1

Characterization of rIL10-treated tolerogenic DC. (A) DC were stained with PE-conjugated mAb specific for IA/IE, H2kb, PD-L1, PD-L2, B7-1, B7-2, and CD11c and analyzed by FACS. Percent of positively stained cells was compared to isotype controls. Results are shown as mean±SD of four independent experiments. * p≤0.05, IL-10-treated DC compared to non-treated controls. (B) 10 μg of DC lysate from rIL-10-treated and control groups were run on SDS-PAGE gels under non-reducing conditions and immunoblotted for B7-1, B7-2 or beta-actin as control. (C) IL-10 treated and non-treated DC were stimulated with 100 ng/mL LPS overnight on day 7 of culture. IL-6, IL-23, IL-12 p70 and IL-12/IL23 total p40 levels in DC culture supernatant were determined on day 8 using ELISA. p≤0.05, DC.Non+LPS group compared to the other three groups. **p≤0.05, DC.IL-10+LPS group compared to the other three groups.